Infinity PhII results a blow for PI3K in inflammation
Infinity Pharmaceuticals has discontinued development of its oral PI3K inhibitor duvelisib in rheumatoid arthritis after the candidate failed in a Phase II trial.
Infinity Pharmaceuticals has discontinued development of its oral PI3K inhibitor duvelisib in rheumatoid arthritis after the candidate failed in a Phase II trial.